European Heart Journal Advance Access originally published online on June 16, 2006
European Heart Journal 2006 27(20):2400-2405; doi:10.1093/eurheartj/ehl094
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial
1 Heart Institute, Good Samaritan Hospital, Cardiovascular Division of the Keck School of Medicine at University of Southern California, 1225 Wilshire Boulevard, Los Angeles, CA 90017, USA
2 North Atlanta Cardiovascular Associates, P.C., Atlanta, Georgia
3 Division of Cardiovascular Disease and Internal Medicine, Mayo Clinic, Rochester, MN, USA
4 Department of Medicine, George, Washington University, Washington, DC, USA
5 Department of Medicine, Emory University School of Medicine, Atlanta, Georgia
6 Columbia University Medical Center and the, Cardiovascular Research Foundation, New York, NY, USA
Received 25 March 2006; revised 19 May 2006; accepted 26 May 2006; online publish-ahead-of-print 16 June 2006.
* Corresponding author. +1 213 977 4040 or 977-4050; fax: +1 213 977 4107. E-mail address: rkloner{at}goodsam.org
See page 2376 for the editorial comment on this article (doi:10.1093/eurheartj/ehl268)
Aims The purpose of this analysis was to determine whether the efficacy of adenosine vs. placebo was dependent on the timing of reperfusion therapy in the second Acute Myocardial Infarction Study of Adenosine (AMISTAD-II).
Methods and results Patients presenting with ST-segment elevation anterior AMI were randomized to receive placebo vs. adenosine (50 or 70 µg/kg/min) for 3 h starting within 15 min of reperfusion therapy. In the present post hoc hypothesis generating study, the results were stratified according to the timing of reperfusion, i.e.
or < the median 3.17 h, and by reperfusion modality. In patients receiving reperfusion <3.17 h, adenosine compared with placebo significantly reduced 1-month mortality (5.2 vs. 9.2%, respectively, P=0.014), 6-month mortality (7.3 vs. 11.2%, P=0.033), and the occurrence of the primary 6-month composite clinical endpoint of death, in-hospital CHF, or rehospitalization for CHF at 6 months (12.0 vs. 17.2%, P=0.022). Patients reperfused beyond 3 h did not benefit from adenosine.
Conclusion In this post hoc analysis, 3 h adenosine infusion administered as an adjunct to reperfusion therapy within the first 3.17 h onset of evolving anterior ST-segment elevation AMI enhanced early and late survival, and reduced the composite clinical endpoint of death or CHF at 6 months.
Key Words: Adenosine Myocardial infarction Thrombolysis Fibrinolytic therapy Percutaneous transluminal coronary angioplasty Congestive heart failure
![]()
CiteULike
Connotea
Del.icio.us What's this?
Related articles in EHJ:
- Adenosine as an adjunct to reperfusion in myocardial infarction
- Gerald Maurer
EHJ 2006 27: 2376-2377.[Extract] [FREE Full Text]
This article has been cited by other articles:
![]() |
A. Prasad, G. W. Stone, D. R. Holmes, and B. Gersh Reperfusion Injury, Microvascular Dysfunction, and Cardioprotection: The "Dark Side" of Reperfusion Circulation, November 24, 2009; 120(21): 2105 - 2112. [Full Text] [PDF] |
||||
![]() |
M. L. Fokkema, P. J. Vlaar, M. Vogelzang, Y. L. Gu, M. A. Kampinga, B. J. de Smet, G. A. Jessurun, R. L. Anthonio, A. F. van den Heuvel, E.-S. Tan, et al. Effect of High-Dose Intracoronary Adenosine Administration During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: A Randomized Controlled Trial Circ Cardiovasc Interv, August 1, 2009; 2(4): 323 - 329. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Sipido, A. Tedgui, S. D. Kristensen, G. Pasterkamp, H. Schunkert, M. Wehling, P. G. Steg, W. Eisert, F. Rademakers, B. Casadei, et al. Identifying needs and opportunities for advancing translational research in cardiovascular disease Cardiovasc Res, August 1, 2009; 83(3): 425 - 435. [Full Text] [PDF] |
||||
![]() |
J. N. Peart and J. P. Headrick Clinical cardioprotection and the value of conditioning responses Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1705 - H1720. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Forrester, A. J. White, S. Matsushita, T. Chakravarty, and R. R. Makkar New Paradigms of Myocardial Regeneration Post-Infarction: Tissue Preservation, Cell Environment, and Pluripotent Cell Sources J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Velot, B. Haas, F. Leonard, I. Ernens, M. Rolland-Turner, C. Schwartz, D. Longrois, Y. Devaux, and D. R. Wagner Activation of the adenosine-A3 receptor stimulates matrix metalloproteinase-9 secretion by macrophages Cardiovasc Res, November 1, 2008; 80(2): 246 - 254. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions Circulation, July 29, 2008; 118(5): 552 - 566. [Full Text] [PDF] |
||||
![]() |
R. A. Kloner and R. W. Nesto Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection Circulation, May 13, 2008; 117(19): 2523 - 2533. [Full Text] [PDF] |
||||
![]() |
R. Ramaraj, M. B. Forman, E. K. Jackson, C. J. Lowenstein, B. Ibanez, G. Cimmino, J. J. Badimon, P. G. Korantzopoulos, J. A. Goudevenos, D. M. Yellon, et al. Myocardial Reperfusion Injury N. Engl. J. Med., December 6, 2007; 357(23): 2408 - 2410. [Full Text] [PDF] |
||||
![]() |
D. M. Yellon and D. J. Hausenloy Myocardial Reperfusion Injury N. Engl. J. Med., September 13, 2007; 357(11): 1121 - 1135. [Full Text] [PDF] |
||||
![]() |
C. B. Granger and M. R. Patel The Search for Myocardial Protection: Is There Still Hope? J. Am. Coll. Cardiol., July 31, 2007; 50(5): 406 - 408. [Full Text] [PDF] |
||||
![]() |
M. T. Dirksen, G. J. Laarman, M. L. Simoons, and D. J.G.M. Duncker Reperfusion injury in humans: A review of clinical trials on reperfusion injury inhibitory strategies Cardiovasc Res, June 1, 2007; 74(3): 343 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
The APEX AMI Investigators Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA, January 3, 2007; 297(1): 43 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Maurer Adenosine as an adjunct to reperfusion in myocardial infarction Eur. Heart J., October 2, 2006; 27(20): 2376 - 2377. [Full Text] [PDF] |
||||








